Meeting
2020 ASCO Virtual Scientific Program
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.
Authors
David F. McDermott
Dana-Farber/Harvard Cancer Center, Boston, MA
David F. McDermott , Jae-Lyun Lee , Georg A. Bjarnason , James M. G. Larkin , Rustem Gafanov , Mark D. Kochenderfer , Niels Viggo Jensen , Frede Donskov , Jahangeer Malik , Alexandr Poprach , Scott S. Tykodi , Teresa Alonso Gordoa , Daniel C. Cho , Poul F. Geertsen , Miguel Angel Climent Duran , Christopher Di Simone , Xiaoqi Du , Rodolfo F. Perini , Karla Rodriguez-Lopez , Michael B. Atkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02853344
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5069)
DOI
10.1200/JCO.2020.38.15_suppl.5069
Abstract #
5069
Poster Bd #
138
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).
First Author: Jae-Lyun Lee
Poster
2020 ASCO Virtual Scientific Program
First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.
First Author: Jae-Lyun Lee
First Author: Scott S. Tykodi
Poster
2022 ASCO Annual Meeting
Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.
First Author: Ivan Borbath